+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation



Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation



Blood 77(9): 2065-2071



Forty-seven patients with hematologic neoplasia received recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) by daily 2-hour infusion following allogeneic bone marrow transplantation from HLA-identical sibling donors in a phase I-II dose-escalation trial. Dose levels ranged from 30 to 500 micrograms/m2/d. At doses at or below 250 micrograms/m2/d, toxicity felt to be caused by rhGM-CSF was negligible. However, three of five patients treated with 500 micrograms/m2/d had unacceptable side effects caused by rhGM-CSF. Two different graft-versus-host disease (GVHD) prophylactic regimens were administered. Twenty-seven evaluable patients were administered regimens that did not contain methotrexate (MTX) (Group I) and reached an absolute neutrophil count of 1,000/microL by a median of day 14. In contrast, 18 patients who received GVHD prophylactic regimens containing MTX (Group II) reached an absolute neutrophil count of 1,000/microL on a median of day 20. Patients in Group I had fewer febrile days and, of those discharged, had shorter initial hospitalizations than patients in Group II. The overall incidence of severe acute GVHD (grade 2 or greater) in the rhGM-CSF-treated patients was 28% and was similar to that in historical "good risk" patients who did not receive rhGM-CSF. These preliminary data suggest rhGM-CSF is unlikely to exacerbate GVHD in HLA-identical sibling donor transplants and indicate the need for randomized trials of rhGM-CSF in allogeneic marrow transplant patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040963735

Download citation: RISBibTeXText

PMID: 1902125


Related references

Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 79(10): 2572-2577, 1992

Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Japanese Journal of Clinical Oncology 24(4): 205-211, 1994

Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Experimental Hematology 19(9): 868-873, 1991

The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation. Cancer Investigation 11(2): 224-228, 1993

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 79(5): 1359-1365, 1992

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 84(2): 133-137, 1999

Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non hodgkin's lymphoma blood and bone marrow progenitor growth studies a phase ii eastern cooperative oncology group trial. Blood 78(3): 830-837, 1991

A multicenter double blind randomized trial of recombinant human granulocyte macrophage colony stimulating factor gm csf in recipients of allogeneic t cell depleted bone marrow. Bone Marrow Transplantation 5(Suppl. 2): 40, 1990

Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial. Pediatric Transplantation 4(2): 123-131, 2000

Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation. Transplantation Proceedings 25(4 Suppl 3): 57-60, 1993

Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. Journal of Clinical Oncology 15(4): 1617-1623, 1997

Recombinant human granulocyte colony stimulating factor for allogeneic bone marrow transplantation. Proceedings of the American Association for Cancer Research Annual Meeting 31: 173, 1990

Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Experimental Hematology 17(10): 1047-1050, 1989

Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Chinese Medical Journal 109(11): 827-831, 1996